Estrogen positive breast cancer recurrence during tamoxifen therapy: microdissected tumor
Summary:
Expression profiling of microdissected estrogen positive primary breast cancer tumors from 60 patients. Patients later treated with tamoxifen for 5 years, and tumors grouped according to whether cancer recurred. Results identify markers of disease-free survival that include HOXB13 and IL17BR.
GPL1223:
Arcturus 22k human oligonucleotide microarray
Citations:
Ma XJ, Wang Z, Ryan PD, Isakoff SJ et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004 Jun;5(6):607-16. PMID: 15193263
Loi S, Haibe-Kains B, Desmedt C, Wirapati P et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008 May 22;9:239. PMID: 18498629
